iSpecimen Inc. (NASDAQ:ISPC) Sees Significant Growth in Short Interest

iSpecimen Inc. (NASDAQ:ISPC) was the recipient of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 241,056 shares, an increase of 113.6% from the May 14th total of 112,840 shares. Approximately 19.1% of the shares of the company are sold short. Based on an average trading volume of 386,118 shares, the days-to-cover ratio is presently 0.6 days.

iSpecimen Stock Performance

Shares of iSpecimen stock opened at $2.85 on Monday. The stock has a market cap of $4.09 million, a P/E ratio of -0.04 and a beta of 1.62. The stock’s fifty day moving average is $4.39 and its 200 day moving average is $9.87. iSpecimen has a one year low of $2.54 and a one year high of $127.20.

iSpecimen (NASDAQ:ISPC) last issued its quarterly earnings results on Friday, May 15th. The company reported ($6.66) EPS for the quarter. iSpecimen had a negative return on equity of 584.65% and a negative net margin of 1,080.16%.The company had revenue of $0.16 million during the quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ISPC. Wall Street Zen upgraded shares of iSpecimen to a “sell” rating in a research report on Saturday, May 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of iSpecimen in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Institutional Trading of iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Virtu Financial LLC acquired a new stake in iSpecimen Inc. (NASDAQ:ISPC) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned about 0.65% of iSpecimen as of its most recent SEC filing. Institutional investors and hedge funds own 13.62% of the company’s stock.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.